Skip to main content
Raphael Szalat, MD, Hematology, Boston, MA

Raphael Elie Szalat MD

Hematologic Oncology


Physician

Join to View Full Profile
  • 830 Harrison Avenue 3rd FLMoakley BldgBoston, MA 02118

  • Phone+1 617-638-6428

  • Fax+1 617-638-5756

Dr. Szalat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • I am specialized in clinical immunology and hematology, translational and genomics research. After 5 years at the DFCI/Harvard Medical school as a research fellow, working on multiple myeloma biology, I am now back in the clinic as a clinical fellow at Boston Medical Center/Boston University in hematology oncology. I did my medical training in Paris, France at the assistance publique des hopitaux de Paris (APHP) in internal medicine and Immunology-hematology. I specialized in clinical Immunology and I have a Master in Immunology from Paris Descartes and the Pasteur Institute and a PhD in Hematology from Paris La Sorbonne. During my training, I participated as a co-investigator to several clinical trials and I am looking forward on continuing working on plasma cells disorders and lymphoid malignancies.

Education & Training

  • Paris VI University School of Medicine
    Paris VI University School of MedicineClass of 2004

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2018 - 2026

Publications & Presentations

PubMed

Abstracts/Posters

  • Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study
    Raphael Szalat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Emerging Therapies for Multiple Myeloma
    Emerging Therapies for Multiple MyelomaMay 30th, 2019
  • Recent FDA Rulings on Multiple Myeloma Treatments
    Recent FDA Rulings on Multiple Myeloma TreatmentsApril 4th, 2019

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: